127 related articles for article (PubMed ID: 20816259)
1. Thyroid-associated orbitopathy.
Tarabishy AB; Lewis CD; Perry JD
Ophthalmology; 2010 Sep; 117(9):1864; author reply 1864-5. PubMed ID: 20816259
[No Abstract] [Full Text] [Related]
2. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy.
Khanna D; Chong KK; Afifiyan NF; Hwang CJ; Lee DK; Garneau HC; Goldberg RA; Darwin CH; Smith TJ; Douglas RS
Ophthalmology; 2010 Jan; 117(1):133-139.e2. PubMed ID: 19818507
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for thyroid eye disease.
Oh SR; Priel A; Levi L; Granet DB; Korn BS; Kikkawa DO
Ophthalmology; 2011 Apr; 118(4):792; author reply 792-3. PubMed ID: 21459230
[No Abstract] [Full Text] [Related]
4. Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action.
Salvi M; Vannucchi G; Currò N; Introna M; Rossi S; Bonara P; Covelli D; Dazzi D; Guastella C; Pignataro L; Ratiglia R; Golay J; Beck-Peccoz P
Arch Ophthalmol; 2012 Jan; 130(1):122-4. PubMed ID: 22232486
[No Abstract] [Full Text] [Related]
5. Rituximab for thyroid eye disease.
Silkiss RZ; Reier A; Coleman M; Lauer SA
Ophthalmic Plast Reconstr Surg; 2010; 26(5):310-4. PubMed ID: 20562667
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
[TBL] [Abstract][Full Text] [Related]
7. Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy.
Nielsen JF; El Fassi D; Nielsen CH; Hegedüs L; Lauer SA; Silkiss RZ; Prause JU
Acta Ophthalmol; 2009 Nov; 87(8):927-9. PubMed ID: 19785644
[No Abstract] [Full Text] [Related]
8. The role of intravenous methylprednisolone immunosuppression in the management of active thyroid eye disease.
Tambe K; Bhargava J; Tripathi A; Gregory M; Burns J; Sampath R
Orbit; 2010 Oct; 29(5):227-31. PubMed ID: 20812826
[TBL] [Abstract][Full Text] [Related]
9. Orbital B-lymphocyte depletion in a treatment failure of rituximab for thyroid eye disease.
Gess AJ; Silkiss RZ
Ophthalmic Plast Reconstr Surg; 2014; 30(1):e11-3. PubMed ID: 23531951
[TBL] [Abstract][Full Text] [Related]
10. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.
Bonara P; Vannucchi G; Campi I; Rossi S; Cantoni F; Frugoni C; Sbrozzi F; Guastella C; Avignone S; Beck-Peccoz P; Salvi M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):118-23. PubMed ID: 18270865
[TBL] [Abstract][Full Text] [Related]
11. [Anti-cytokine and anti-lymphocyte monoclonal antibodies in the treatment of thyroid associated ophthalmopathy].
Komorowski J; Jankiewicz-Wika J; Siejka A; Lawnicka H; Stepień H
Pol Merkur Lekarski; 2007 Jun; 22(132):571-4. PubMed ID: 17874632
[TBL] [Abstract][Full Text] [Related]
12. Potential utility of rituximab for Graves' orbitopathy.
Salvi M; Vannucchi G; Beck-Peccoz P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of rituximab monotherapy in multifocal motor neuropathy.
Stieglbauer K; Topakian R; Hinterberger G; Aichner FT
Neuromuscul Disord; 2009 Jul; 19(7):473-5. PubMed ID: 19467601
[TBL] [Abstract][Full Text] [Related]
14. Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease.
El Fassi D; Clemmensen O; Nielsen CH; Silkiss RZ; Hegedüs L
J Clin Endocrinol Metab; 2007 Oct; 92(10):3762-3. PubMed ID: 17933978
[No Abstract] [Full Text] [Related]
15. Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very low-dose rituximab.
Karasek D; Cibickova L; Karhanova M; Kalitova J; Schovanek J; Frysak Z
Endokrynol Pol; 2017; 68(5):498-504. PubMed ID: 28660988
[TBL] [Abstract][Full Text] [Related]
16. Worsening after rituximab treatment in anti-mag neuropathy.
Broglio L; Lauria G
Muscle Nerve; 2005 Sep; 32(3):378-9. PubMed ID: 15986418
[No Abstract] [Full Text] [Related]
17. Rituximab in the treatment of thyroid eye disease: science fiction?
Salvi M; Vannucchi G; Campi I; Beck-Peccoz P
Orbit; 2009; 28(4):251-5. PubMed ID: 19839884
[TBL] [Abstract][Full Text] [Related]
18. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab.
Schmidt E; Herzog S; Bröcker EB; Zillikens D; Goebeler M
Br J Dermatol; 2005 Aug; 153(2):449-51. PubMed ID: 16086770
[No Abstract] [Full Text] [Related]
19. Novel treatment modalities for Graves' orbitopathy.
Bartalena L; Lai A; Sassi L; Lombardi V; Dalle Mule I; Gandolfo M; Liparulo L; Azzolini C; Piantanida E; Tanda ML
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():210-6. PubMed ID: 20467365
[TBL] [Abstract][Full Text] [Related]
20. Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab.
McElnea E; Ní Mhéalóid A; Moran S; Kelly R; Fulcher T
Orbit; 2014 Dec; 33(6):424-7. PubMed ID: 25207976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]